目的观察氨氯地平贝那普利复方制剂治疗尿毒症肾性高血压的疗效。方法回顾性分析2018年7月至2019年12月山西汾西矿业(集团)有限责任公司职工总医院收治的尿毒症肾性高血压患者60例的临床资料,根据治疗方案不同分为贝那普利治疗(对照组)...目的观察氨氯地平贝那普利复方制剂治疗尿毒症肾性高血压的疗效。方法回顾性分析2018年7月至2019年12月山西汾西矿业(集团)有限责任公司职工总医院收治的尿毒症肾性高血压患者60例的临床资料,根据治疗方案不同分为贝那普利治疗(对照组)和氨氯地平贝那普利复方制剂治疗(观察组),每组30例。比较两组治疗前、治疗2周后血压值、24 h平均舒张压/收缩压变异性(24 h DBPV、24 h SBPV)、血尿素氮(BUN)、血肌酐(Scr)及用药安全性。结果治疗前,两组血压及血压变异性比较,差异均无统计学意义(t=0.019、0.322、0.106、0.027,均P>0.05);治疗2周后,两组收缩压、舒张压及24 h SBPV、24 h DBPV均降低,且观察组均低于对照组,差异均有统计学意义[(132.38±9.16)mmHg比(142.27±9.17)mmHg,(80.17±5.05)mmHg比(85.67±6.49)mmHg,(9.23±1.45)mmHg比(11.77±1.68)mmHg,(7.02±0.69)mmHg比(8.79±0.81)mmHg,t=4.179、3.663、9.111、6.269,均P<0.05]。两组BUN、Scr差异均无统计学意义(t=0.198、0.301、均P>0.05)。两组不良反应发生率比较,差异无统计学意义[26.66%(8/30)比20.00% (6/30),χ^(2)=0.373,P>0.05]。结论氨氯地平贝那普利复合制剂对于尿毒症肾性高血压患者的降压作用更明显,能降低血压变异性,临床安全性高。展开更多
During the tests of glomerular filtration function,serum creatinine,urea and endogenous creatinine clearance rate are the most commonly used indicators,which possess many disadvantages.Currently,a large number of stud...During the tests of glomerular filtration function,serum creatinine,urea and endogenous creatinine clearance rate are the most commonly used indicators,which possess many disadvantages.Currently,a large number of studies have been conducted on investigating new indicators reflecting changes in glomerular filtration rate.As a low-molecular weight protein,cystatin C is a member of cysteine protease inhibitor superfamily,which can be produced by all the nucleated cells in vivo with a stable generation rate.In the circulation process in vivo,cystatin C can only be removed via glomerular filtration,which is an ideal endogenous marker reflecting changes in glomerular filtration rate.Serum cystatin C concentration is superior to serum creatinine concentration in renal function tests.展开更多
文摘目的观察氨氯地平贝那普利复方制剂治疗尿毒症肾性高血压的疗效。方法回顾性分析2018年7月至2019年12月山西汾西矿业(集团)有限责任公司职工总医院收治的尿毒症肾性高血压患者60例的临床资料,根据治疗方案不同分为贝那普利治疗(对照组)和氨氯地平贝那普利复方制剂治疗(观察组),每组30例。比较两组治疗前、治疗2周后血压值、24 h平均舒张压/收缩压变异性(24 h DBPV、24 h SBPV)、血尿素氮(BUN)、血肌酐(Scr)及用药安全性。结果治疗前,两组血压及血压变异性比较,差异均无统计学意义(t=0.019、0.322、0.106、0.027,均P>0.05);治疗2周后,两组收缩压、舒张压及24 h SBPV、24 h DBPV均降低,且观察组均低于对照组,差异均有统计学意义[(132.38±9.16)mmHg比(142.27±9.17)mmHg,(80.17±5.05)mmHg比(85.67±6.49)mmHg,(9.23±1.45)mmHg比(11.77±1.68)mmHg,(7.02±0.69)mmHg比(8.79±0.81)mmHg,t=4.179、3.663、9.111、6.269,均P<0.05]。两组BUN、Scr差异均无统计学意义(t=0.198、0.301、均P>0.05)。两组不良反应发生率比较,差异无统计学意义[26.66%(8/30)比20.00% (6/30),χ^(2)=0.373,P>0.05]。结论氨氯地平贝那普利复合制剂对于尿毒症肾性高血压患者的降压作用更明显,能降低血压变异性,临床安全性高。
文摘During the tests of glomerular filtration function,serum creatinine,urea and endogenous creatinine clearance rate are the most commonly used indicators,which possess many disadvantages.Currently,a large number of studies have been conducted on investigating new indicators reflecting changes in glomerular filtration rate.As a low-molecular weight protein,cystatin C is a member of cysteine protease inhibitor superfamily,which can be produced by all the nucleated cells in vivo with a stable generation rate.In the circulation process in vivo,cystatin C can only be removed via glomerular filtration,which is an ideal endogenous marker reflecting changes in glomerular filtration rate.Serum cystatin C concentration is superior to serum creatinine concentration in renal function tests.
